Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements

被引：0

作者：

Sherkow, Jacob S. ^{[1
]}

机构：

[1] Stanford Law Sch, Ctr Law & Biosci, Stanford, CA 94305 USA

来源：

NATURE BIOTECHNOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1038/nbt.2542

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmaceutical companies today.

引用

页码：316 / 318

页数：3

共 12 条

[1] Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements
Jacob S Sherkow
[J]. Nature Biotechnology, 2013, 31 : 316 - 317
[2] Do "Reverse Payment" Settlements Constitute an Anticompetitive Pay-for-Delay?
Drake, Keith
Starr, Martha
McGuire, Thomas
[J]. INTERNATIONAL JOURNAL OF THE ECONOMICS OF BUSINESS, 2015, 22 (02) : 173 - 200
[3] Federal Trade Commission, Petitioner, v. Actavis, Inc., et al., Respondents (Supreme Court of the United States)
Andrews, Cory L.
Samp, Richard A.
Mcdonald, Kevin D.
[J]. BIOTECHNOLOGY LAW REPORT, 2013, 32 (03) : 204 - 215
[4] “Actavis”Federal Trade Commission Act, § 5, 15 U.S.C. § 45 – Federal Trade Commission v. Actavis
[J]. IIC - International Review of Intellectual Property and Competition Law, 2013, 44 (7) : 848 - 850
[5] The Fate of FTC v. Actavis, Inc. in the Biosimilar Context-Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers?
Ho, Nicola Gabrielle
[J]. BIOTECHNOLOGY LAW REPORT, 2022, 41 (04) : 194 - 199
[6] AN EVENT STUDY OF PERINDOPRIL (SERVIER) REVERSE PAYMENT PATENT SETTLEMENTS' CASE: IS KRKA TRULY AN EXCEPTION WITHIN THE PAY-FOR-DELAY COMMISSION DECISION?
Ocepek, France
[J]. LEXONOMICA, 2023, 15 (01): : 121 - 146
[7] US Supreme Court decision on reverse payment agreements: new era in patent litigation settlements - FTC v Actavis, Inc., 570 US (2013)
Gurgula, Olga
[J]. QUEEN MARY JOURNAL OF INTELLECTUAL PROPERTY, 2013, 3 (04) : 325 - 335
[8] The global reach of FTC v. actavis-Will europe differ from the US approach to pay-for-delay agreements?
Gürkaynak G.
Güner A.
Filson J.
[J]. IIC - International Review of Intellectual Property and Competition Law, 2014, 45 (2) : 128 - 160
[9] UCB, Inc. v. Actavis Lab'ys UT, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 679
Holman, Christopher M.
[J]. BIOTECHNOLOGY LAW REPORT, 2023, 42 (03) : 154 - 164
[10] Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc. United States Court of Appeals of the Federal Circuit, 2022 No. 2021-1495, 2022 WL 2525318 (non-precedential)
Holman, Christopher M.
[J]. BIOTECHNOLOGY LAW REPORT, 2022, 41 (05) : 262 - 266

← 1 2 →